Our Latest Stories
Our Science
June 19, 2025
Digital and AI Powered Manufacturing & Supply: Delivering Faster and Safer for Patients
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
86
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
June 20, 2025
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
June 17, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue
June 15, 2025
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
June 12, 2025
Media Update: EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US